secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2022-01-05T23:59:59+00:00
Accession:  0001104659-22-001252
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle reports 1 confirmed complete response in BT8009 Phase I; management restructured
--------------------------------------------------------------------------------

- BT8009 Phase I: 4/11 partial responses; one confirmed complete response (100% tumor reduction) at 5.0 mg/m2.
- Dose escalation continues at 7.5 mg/m2; interim Phase I results to be presented at a 2022 medical meeting.
- BT5528 Phase I/II on track to initiate expansion cohorts in 2022 with RP2D of 6.5 mg/m2 every-other-week.
- BT7480 Phase I dose escalation ongoing; four SITC posters on Bicycle TICAs including NK-cell-engaging molecule.
- Michael Skynner becomes CTO (new role); Alistair Milnes promoted to COO, both effective Jan 3, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465922001252/0001104659-22-001252-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465922001252/tm221573d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-001252

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer